| Literature DB >> 35746507 |
Evaggelos-Georgios Stampinas1, Efterpi Bouroutzika1, Panagiotis D Katsoulos2, Georgios Valiakos3, Ekaterini K Theodosiadou1, Labrini V Athanasiou4, Sotiria Makri5, Demetrios Kouretas5, Irene Valasi1.
Abstract
The redox status shortly after the vaccination of pregnant ewes is rather unexploited. Thus, the present study was designed to evaluate the fluctuation of redox status after the administration of the annual booster dose of a polyvalent clostridial vaccine in pregnant ewes, 3 to 4 weeks before lambing, with or without a simultaneous injection of Vit E/Se. In total, 24 pregnant Lacaune ewes 3-4 weeks before lambing were randomly allocated into four equal groups: the V (vaccinated with a polyvalent clostridial vaccine), VE (vaccinated and injected IM with Vit E/Se), E (injected IM with Vit E and Se), and C (neither vaccinated nor injected with Vit E/Se). The study period lasted for 21 days, starting on the day of administration. Four redox biomarkers, the antioxidant capacity (TAC), the thiobarbituric acid reactive substances (TBARS), the reduced glutathione (GSH), and the catalase (CAT) were evaluated in blood samples collected from all ewes before the injections (0 h) and then at 12 (12 h), 24 (D1), and 48 h (D2), and thereafter on days 4 (D4), 6 (D6), 10 (D10), 14 (D14), and 21 (D21). The results reveal that the TAC was the only biomarker evaluated that was significantly affected by group and significantly lower in vaccinated animals (V and VE groups) compared to non-vaccinated (E and C groups). The absence of an increase in the TBARS values after vaccination in groups V and VE indicates the absence of significant oxidative stress. Overall, it can be assumed that annual booster immunizations against clostridial diseases do not impose acute oxidative stress on pregnant ewes in the last month of pregnancy.Entities:
Keywords: ewes; polyvalent clostridial vaccine; pregnancy; redox status; selenium; vitamin E
Year: 2022 PMID: 35746507 PMCID: PMC9229268 DOI: 10.3390/vaccines10060898
Source DB: PubMed Journal: Vaccines (Basel) ISSN: 2076-393X
Figure 1Experimental overview of the study.
Effects (p values) of group, day of sampling (day), and their interactions on the concentrations of the selected redox biomarkers evaluated (TAC, GSH, TBARS, and CAT).
| Effect | Redox Biomarkers | |||
|---|---|---|---|---|
| TAC | GSH | TBARS | CAT | |
| Group | <0.001 | 0.042 | 0.153 | 0.670 |
| Day | <0.001 | <0.001 | <0.001 | <0.001 |
| Group × day | <0.001 | <0.001 | 0.004 | 0.093 |
Post-hoc comparisons of marginal mean ± SE values of TAC (mmol DPPH/L) throughout the study period among groups and sampling days, and post-hoc comparison of mean ± SE TAC values obtained at each sampling among sampling days within each group and among groups within sampling days.
| Time Relative to Administrations | Group | Marginal Sampling Day Mean | |||
|---|---|---|---|---|---|
| Control | E | V | VE | ||
| 0 h | 0.61 ± 0.03 aA | 0.47 ± 0.05 abcA | 0.60 ± 0.01 bA | 0.45 ± 0.04 bcA | 0.52 ± 0.03 cd |
| 12 h | 0.51 ± 0.04 aA | 0.58 ± 0.04 bcA | 0.42 ± 0.07 abA | 0.50 ± 0.11 bcA | 0.51 ± 0.03 cd |
| D1 | 0.55 ± 0.04 aA | 0.59 ± 0.05 bcA | 0.59 ± 0.03 bA | 0.67 ± 0.03 cA | 0.59 ± 0.03 d |
| D2 | 0.67 ± 0.05 aA | 0.63 ± 0.15 cA | 0.24 ± 0.04 aB | 0.33 ± 0.01 abB | 0.46 ± 0.03 bc |
| D4 | 0.46 ± 0.01 aA | 0.55 ± 0.03 bcA | 0.41 ± 0.02 abA | 0.39 ± 0.03 bA | 0.44 ± 0.03 bc |
| D6 | 0.41 ± 0.04 aA | 0.33 ± 0.02 aA | 0.35 ± 0.03 abA | 0.41 ± 0.04 bA | 0.37 ± 0.03 ab |
| D10 | 0.59 ± 0.05 aA | 0.57 ± 0.03 bcA | 0.20 ± 0.05 aB | 0.14 ± 0.02 aB | 0.37 ± 0.03 ab |
| D14 | 0.69 ± 0.03 aA | 0.56 ± 0.03 bcAC | 0.28 ± 0.02 aB | 0.33 ± 0.03 abC | 0.45 ± 0.03 bc |
| D21 | 0.35 ± 0.04 aA | 0.32 ± 0.04 aA | 0.26 ± 0.03 aA | 0.34 ± 0.02 abA | 0.31 ± 0.03 a |
| Marginal group mean | 0.53 ± 0.02 A | 0.50 ± 0.02 A | 0.37 ± 0.02 B | 0.41 ± 0.02 B | |
A,B,C—Different superscripts in the same row denote significant difference (p < 0.05). a,b,c,d—Different superscripts in the same column denote significant difference (p < 0.05). 0 h: pre-treatment; 12 h: 12 h post-treatment; D1 to D21: days 1 to 21 post-treatment.
Post-hoc comparisons of marginal mean ± SE values of GSH (μmol/gr Hb) throughout the study period among groups and sampling days, and post-hoc comparison of mean ± SE GSH values obtained at each sampling among sampling days within each group and among groups within sampling days.
| Time Relative to Administrations | Group | Marginal Sampling Day Mean | |||
|---|---|---|---|---|---|
| Control | E | V | VE | ||
| 0 h | 1.59 ± 0.35 aA | 1.75 ± 0.09 aA | 2.34 ± 0.37 abA | 2.08 ± 0.37 aA | 2.02 ± 0.23 ab |
| 12 h | 1.26 ± 0.23 aA | 2.26 ± 0.21 aA | 1.61 ± 0.28 aA | 2.06 ± 0.37 aA | 1.87 ± 0.23 a |
| D1 | 3.58 ± 0.30 aA | 9.40 ± 1.18 cB | 3.88 ± 0.46 abcA | 3.46 ± 0.76 abA | 5.17 ± 0.23 e |
| D2 | 3.73 ± 0.63 aA | 5.60 ± 0.30 bA | 3.64 ± 0.39 abcA | 4.18 ± 0.48 abA | 4.36 ± 0.23 de |
| D4 | 2.19 ± 0.51 aA | 3.28 ± 0.39 abA | 2.66 ± 0.18 abcA | 2.68 ± 0.52 abA | 2.78 ± 0.23 ab |
| D6 | 1.69 ± 0.27 aA | 3.00 ± 0.20 aA | 4.10 ± 0.46 bcA | 3.99 ± 0.74 abA | 3.27 ± 0.23 c |
| D10 | 2.30 ± 0.78 aA | 3.20 ± 0.36 aA | 2.93 ± 0.59 abcA | 3.91 ± 0.44 abA | 3.16 ± 0.23 bc |
| D14 | 1.15 ± 0.23 aA | 1.66 ± 0.30 aA | 3.48 ± 0.65 abcAB | 5.02 ± 0.58 bB | 2.90 ± 0.23 b |
| D21 | 2.86 ± 0.70 aA | 3.53 ± 0.30 abA | 4.81 ± 0.44 cA | 4.14 ± 0.59 abA | 3.91 ± 0.23 cd |
| Marginal group mean | 2.47 ± 0.34 A | 3.82 ± 0.31 B | 3.35 ± 0.31 AB | 3.58 ± 0.31 AB | |
A,B Different superscripts at the same row denote significant difference (p < 0.05).a,b,c,d,e Different superscripts at the same column denote significant difference (p < 0.05). 0 h: pre-treatment; 12 h: 12 h post-treatment; D1 to D21: days 1 to 21 post-treatment.
Post-hoc comparisons of marginal mean ± SE values of TBARS (μmol/L) throughout the study period among groups and sampling days, and post-hoc comparison of mean ± SE TBARS values obtained at each sampling among sampling days within each group and among groups within sampling days.
| Time Relative to Administrations | Group | Marginal Sampling Day Mean | |||
|---|---|---|---|---|---|
| Control | E | V | VE | ||
| 0 h | 5.24 ± 0.53 aA | 4.24 ± 0.81 abA | 4.55 ± 0.75 bA | 6.08 ± 0.26 bA | 5.05 ± 0.28 cd |
| 12 h | 2.93 ± 0.31 aA | 2.27 ± 0.23 aA | 1.54 ± 0.13 aA | 3.05 ± 0.79 aA | 2.47 ± 0.28 a |
| D1 | 3.18 ± 0.40 aA | 3.76 ± 0.56 abA | 4.87 ± 0.98 bA | 4.75 ± 0.52 abA | 4.16 ± 0.28 bcd |
| D2 | 3.80 ± 0.26 aA | 5.03 ± 0.65 abA | 5.38 ± 0.28 bA | 6.16 ± 0.92 bA | 5.12 ± 0.28 d |
| D4 | 4.00 ± 0.39 aA | 4.21 ± 0.56 abA | 3.74 ± 0.99 abA | 3.43 ± 0.32 abA | 3.86 ± 0.28 bc |
| D6 | 4.12 ± 0.41 aA | 3.13 ± 0.23 abA | 4.60 ± 0.21 bA | 5.96 ± 0.73 abA | 4.48 ± 0.28 bcd |
| D10 | 4.87 ± 0.52 aA | 5.27 ± 0.57 bA | 3.63 ± 0.14 abA | 3.94 ± 0.43 abA | 4.45 ± 0.28 bcd |
| D14 | 4.57 ± 0.72 aA | 3.73 ± 0.23 abA | 4.75 ± 0.29 bA | 4.31 ± 0.12 abA | 4.36 ± 0.28 bcd |
| D21 | 2.81 ± 0.26 aA | 3.16 ± 0.26 abA | 4.83 ± 0.35 bA | 4.27 ± 0.23 abA | 3.79 ± 0.28 b |
| Marginal group mean | 3.97 ± 0.20 A | 3.89 ± 0.20 A | 4.23 ± 0.20 A | 4.68 ± 0.20 A | |
A Same superscript in the same row denotes non-significant difference (p > 0.05).a,b,c,d Different superscripts in the same column denote significant difference (p < 0.05). 0 h: pre-treatment; 12 h: 12 h post-treatment; D1 to D21: days 1 to 21 post-treatment.
Post-hoc comparisons of marginal mean ± SE values of CAT (U/mg Hb) throughout the study period among groups and sampling days, and post-hoc comparison of mean ± SE CAT values obtained at each sampling among sampling days within each group and among groups within sampling days.
| Time Relative to Administrations | Group | Marginal Sampling Day Mean | |||
|---|---|---|---|---|---|
| Control | E | V | VE | ||
| 0 h | 32.04 ± 2.33 abA | 38.43 ± 1.69 abA | 37.86 ± 4.15 abA | 34.97 ± 3.06 abA | 35.86 ± 2.15 ab |
| 12 h | 41.83 ± 2.46 abA | 52.23 ± 3.28 abA | 40.29 ± 3.52 abA | 48.41 ± 5.51 abA | 45.72 ± 2.15 cd |
| D1 | 43.68 ± 4.85 abA | 42.13 ± 4.62 abA | 36.96 ± 3.25 abA | 41.07 ± 4.63 abA | 40.99 ± 2.15 abc |
| D2 | 49.95 ± 3.27 abA | 42.85 ± 2.70 abA | 35.45 ± 2.23 aA | 39.67 ± 1.87 abA | 42.01 ± 2.15 abc |
| D4 | 38.54 ± 2.23 abA | 38.83 ± 2.49 abA | 40.83 ± 6.55 abA | 28.07 ± 2.32 aA | 36.60 ± 2.15 abc |
| D6 | 27.70 ± 0.67 aA | 31.68 ± 3.25 aA | 39.89 ± 2.28 abA | 35.41 ± 4.51 abA | 33.70 ± 2.15 a |
| D10 | 48.85 ± 8.13 abA | 46.31 ± 3.19 abA | 54.11 ± 6.72 abA | 51.77 ± 3.82 bcA | 50.29 ± 2.15 d |
| D14 | 58.32 ± 5.87 bA | 69.74 ± 4.26 bA | 61.44 ± 7.15 bA | 63.29 ± 4.11 cA | 63.23 ± 2.15 e |
| D21 | 48.27 ± 6.88 abA | 48.57 ± 3.24 abA | 38.09 ± 4.19 abA | 41.33 ± 4.80 abA | 44.09 ± 2.15 abcd |
| Marginal group mean | 43.27 ± 2.19 A | 45.67 ± 2.19 A | 42.8 ± 2.19 A | 42.70 ± 2.19 A | |
A Same superscript in the same row denotes non-significant difference (p > 0.05). a,b,c,d,e Different superscripts in the same column denote significant difference (p < 0.05). 0 h: pre-treatment; 12 h: 12 h post-treatment; D1 to D21: days 1 to 21 post-treatment.